GlassScriptPhysician profile
Akua Akuffo
NPI 1386124618
$4,421.75
in general payments reported to CMS, 2019-2025
33 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $939 · 2022: $628 · 2023: $638 · 2024: $680 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.25 | 2021-2025 | Botox, Lupron Depot |
| Sumitomo Pharma America, INC. | $646.78 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $477.89 | 2021-2025 | Erleada, Akeega, Carvykti |
| Procept Biorobotics Corporation | $472.26 | 2023-2025 | Aquabeam Robotic System |
| Axonics, INC. | $223.12 | 2021-2022 | |
| Rochester Medical Corporation | $222.36 | 2021-2022 | |
| Teleflex LLC | $169.32 | 2021 | |
| Dendreon Pharmaceuticals LLC | $149.25 | 2021-2022 | |
| Medtronic, INC. | $117.54 | 2025 | Interstim |
| Antares Pharma, INC. | $115.30 | 2021-2025 | Xyosted |
| Urogen Pharma, INC. | $108.02 | 2023-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $106.82 | 2025 | Adstiladrin |
| Urovant Sciences INC | $103.92 | 2022 | |
| Merck Sharp & Dohme LLC | $100.49 | 2021-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $97.98 | 2025 | Xtandi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $94.14 | 2021 | |
| Tolmar, INC. | $63.21 | 2023-2025 | Eligard, Rubraca, Jatenzo |
| Mission Pharmacal Company | $59.09 | 2021-2023 | Uribel |
| Blue Earth Diagnostics | $53.77 | 2021 | |
| Olympus America INC. | $50.31 | 2022-2024 | Itind System |
| Progenics Pharmaceuticals, INC. | $45.04 | 2025 | |
| Coloplast Corp | $29.33 | 2023-2024 | Speedicath |
| Vertex Pharmaceuticals Incorporated | $27.79 | 2025 | |
| Tempus Ai, INC | $26.52 | 2024 | |
| Hollister Incorporated | $26.14 | 2023 | Vapro Pocket, Infyna Chic, Onli |
| Alnylam Pharmaceuticals INC. | $23.47 | 2024 | Oxlumo |
| Convatec INC. | $23.13 | 2022 | |
| Myovant Sciences INC. | $23.06 | 2021 | |
| Laborie Medical Technologies Corp. | $21.98 | 2025 | |
| Pharmaand Gmbh | $21.83 | 2025 | Rubraca |
| Immunitybio, INC. | $16.46 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $15.78 | 2023 | |
| Dentsply Ih INC. | $13.40 | 2023 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akua Akuffo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.